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Abstract Tec family protein tyrosine kinases have in their 
N-terminus two domains. The PH domain is followed by Tec 
homology (TH) domain, which consists of two motifs. The first 
pattern, Btk motif, is also present in some Ras GAP molecules. 
C-terminal half of the TH domain, a proline-rich region, has 
been shown to bind to SH3 domains. Mutations in Bruton's 
tyrosine kinase (Btk) belonging to the Tec family cause X-linked 
agammaglobulinemia (XLA) due to developmental arrest of B 
cells. Here we present the first missense mutations in the TH 
domain. The substitutions affect a conserved pair of cysteines, 
residues 154 and 155, involved in Zn2+ binding and thereby the 
mutations alter protein folding and stability. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The Tec family of cytoplasmic protein tyrosine kinases 
(PTKs) is formed of Btk [1,2], Itk/Tsk [3,4], Tec [5], and 
Bmx [6], which differ from other PTKs by having in the N-ter-
minus two distinct regions called pleckstrin homology (PH) 
and Tec homology (TH) domains [7-9]. Tec family members 
are the only PH domain containing tyrosine kinases and Btk 
is the only protein where PH domain mutations are known to 
have a phenotype. Mutations in Btk cause X-linked agamma-
globulinemia (XLA) in man (e.g. [1,2,10,11]) and X-linked 
immunodeficiency (Xid) in mice [12,13]. XLA is caused by a 
B cell development arrest leading to recurrent infections (for a 
review see [14-18]]. The patients have no or only very few 
mature B cells and consequently immunoglobulins are either 
missing or markedly reduced. 
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The TH domain of about 60-80 residues is located between 
the PH domain and SH3 domain in Tec family members. In 
the N-terminus there is a highly conserved pattern of 25 ami-
no acids, called the Btk motif, which is followed by a proline-
rich region (PRR) [7,8]. The full-length TH domain is present 
only in the Tec family PTKs except for Bmx. PH domain is 
accompanied by Btk motif also in some Ras GTPase activat-
ing proteins (GAPs) [8]. Ras has two forms [19] and several 
functions e.g. in proliferation and differentiation. The inactive 
GDP-bound form can be activated by converting GDP to 
GTP by intrinsic GTPase activity, a process regulated by 
GAPs [20]. The function of the TH domain is unclear, 
although Src family SH3 domains bind to PRR in vitro 
[21-24] and the Btk motif seems to be essential for interac-
tions with G proteins [25,26]. 
The 10 amino acid PRR motifs in Btk interact with the SH3 
domains of Fyn, Lyn and Hck in vitro [21-23], but it is not 
known whether the full-length Src family kinases can associ-
ate. Itk PRR is bound also by the same SH3 domains [21] and 
the corresponding region of Tec binds to Lyn [24]. These 
interactions and the effects of mutations have been discussed 
based on three dimensional structures [16]. Erythropoietin and 
IL3 stimulation induces the specific binding of Vav to Tec 
through the TH domain [56]. Mutations of the key residues 
both in PRR and SH3 domains have been shown to abolish 
binding to SH3 domain [21,23]. An unidentified 72-kDa pro-
tein binds to residues 186-192 in the Btk TH domain [21]. 
Although the Btk gene defect has been characterised from 
more than 400 XLA patients, no missense mutations, except 
for one double mutation containing also a non-sense mutation 
in the PH domain, have been reported from the TH domain 
[10,11,27,28]. Otherwise XLA mutations are relatively evenly 
scattered along the protein. Here, we describe XLA causing 
mutations affecting the conserved residues of the TH domain 
and discuss the function of the Btk and PRR motifs in inter-
actions with cellular signaling partners and structural conse-
quences of mutations. 
2. Materials and methods 
2.1. Immunoprecipitation and in vitro kinase assay 
A synthetic peptide representing Btk amino acids 166-184 coupled 
to keyhole limpet hemocyanin via an N-terminally added cysteine 
residue was used to obtain a Btk antibody by immunisation of rab-
bits. Mononuclear cells (1-2.5 XlO7 cells) were isolated from periph-
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eral blood of XLA patients. After PBS washes, the cells were solubil-
ized in digitonin lysis buffer containing 1% digitonin, 50 mM HEPES 
(pH 7.4), 1 mM DTT, 2 mM EGTA, 2.5 mM EDTA, 1 mM Na3V04 , 
1 mM phenylmethylsulfonyl fluoride, 10 |lg/ml leupeptin, and 10 |Xg/ 
ml aprotinin. After 20 min incubation on ice, detergent-insoluble ma-
terial was removed by centrifugation. Cell lysates were precleared for 
30 min at 4°C with protein A-Sepharose and then mixed with affinity 
purified polyclonal antibodies for 1 h at 4°C. Immune complexes were 
collected by adding Protein A-Sepharose and incubated for an addi-
tional 2 h at 4°C. The Sepharose-protein A-Btk beads were washed 
three times with lysis buffer free from digitonin, EDTA and EGTA. 
The beads were washed two times with kinase buffer containing 
20 mM HEPES (pH 7.4), 10 mM MnCl2, 5 mM MgCl2 and 1 mM 
DTT, 1 mM Na3V04 , 500 uM phenylmethylsulfonyl fluoride, 5 ug/ml 
leupeptin, and 5 ug/ml aprotinin, and finally, the immunoprecipited 
Btk was resuspended in the kinase buffer containing 100 uM ATP. 
Phosphorylation reactions were carried out at room temperature for 
10 min in kinase buffer and terminated by addition of SDS-PAGE 
sample buffer. 
Btk proteins were separated on SDS-PAGE gels and transferred to 
nitrocellulose or Hybond-C extra membrane (Amersham). The blots 
were blocked either in 5 or 10% skim milk or in 2% BSA. Filters were 
developed with secondary antibody conjugated to horseradish perox-
idase using the ECL detection system (Amersham). Total RNA was 
isolated by the guanidium thiocyanate method [29], First strand 
cDNA synthesis was done by using a cDNA synthesis kit according 
to the instructions of the manufacturer (Pharmacia). 
2.2. Mutation analysis 
Purified genomic DNA samples from XLA patients were amplified 
with PCR by using primers designed for each exon. The amplified 
DNA fragments were analysed on polyacrylamide gels. The mutation 
containing exons were analysed by sequencing. As another method 
dideoxy fingerprinting and sequencing of genome DNA was used as 
previously described [30]. 
2.3. PH-TH and TH expression and purification 
Insert encoding the Btk amino acids 1-215 (PH-TH) was amplified 
by PCR with oligonucleotide primers containing restriction sites for 
Ncol and Sail (5' and 3', respectively) for cloning into Escherichia coli 
expression vector, pBAT4 [31]. The overlap extension PCR technique 
[32] with VentR DNA polymerase (New England Biolabs), was used 
to create the mutants C155S and C155G on the PH-TH construct. 
For TH domain expression an insert encoding Btk amino acids 
137-218 (TH) was amplified by PCR. Oligonucleotide primers had 
restriction sites for Ncol and Xhol. The product was cloned into 
expression vector pGAT2 (Periinen et al., unpublished results) creat-
ing a His-tag with a thrombin digestion site at the N-terminus. The 
GST encoding region was digested with Spel. 
PH-TH constructs were expressed in E. coli BL21(DE3) strain. 
Protein expression was screened in 2 X TY-medium with IPTG induc-
tion for 2 h at 37°C. Expression levels were analyzed using SDS-
PAGE in the Phast System (Pharmacia). Large-scale expression in 
LB medium was done similarly except for induction at 30°C for 3 h. 
The cells were harvested and lysed by sonication in +4°C at PBS 
buffer containing 1% Triton X-100, 4 mM DTT, 0.1 uM aprotinin, 
1 |J,M leupeptin, 1 mM EDTA, 1 mg/ml streptomycin sulphate and 
0.2 mg/ml of lysozyme. The lysate was cleared by centrifugation and 
loaded on SP-Sepharose FF (Pharmacia) column. Elution was with 
0.05 to 1.0 M salt-gradient. Fractions containing PH-TH were pooled 
and concentrated for gel filtration on Superdex 75 column (Pharma-
cia) equilibrated with 10 mM HEPES (pH 7.0), 100 mM NaCl and 
2 mM DTT. The purity of the protein was analyzed with reversed-
phase HPLC using Vydac C4 column (4.6 X 150 mm) equilibrated in 
2% acetonitrile and 0.1% TFA. Bound material was eluted using a 
linear acetonitrile gradient (1.45% per minute up to 60%). 
TH construct was expressed as the PH-TH-constructs, except for 
induction in large-scale fermentation that was at 30°C for 6 h. The 
lysate was cleared by centrifugation at 18000Xg for 45 min. The 
lysate was loaded on Ni2+-NTA-agarose (Qiagen, Germany) column, 
which was washed with 10 volumes of PBS buffer. The protein was 
eluted with PBS after over night thrombin digestion. Fractions con-
taining TH domain were pooled and concentrated for gel filtration on 
Superdex 75 column equilibrated with a buffer containing 20 mM 
phosphate-buffer, pH 6.5 and 50 mM NaCl. 
2.4. PH-TH-SH3-SH2 production and analysis 
The Btk PH-TH-SH3-SH2 fragment encoding amino acids 1-383 
was constructed with PCR similar to the other constructs. The insert 
was cloned in the pBAT4/PHTH1-215 vector using BglU and Xhol 
cloning sites. The large-scale protein expression was as with PH-
TH-constructs, except for induction over night at 16°C in the presence 
of 3% of ethanol. The clarified lysate was loaded on SP-Sepharose FF 
(Pharmacia) column and eluted with 0.05 to 1.0 M salt-gradient. SH2 
domain specific affinity chromatography with L-phosphotyrosine 
coupled Sepharose 6B CL was used as the second purification step. 
Concentrated fractions were gel filtrated on Superdex 75 column. 
The metal analysis was done using inductively coupled plasma mass 
spectroscopy at the Abo Akademi University (Turku, Finland). The 
lyophilised sample (24.5 mg) was dissolved in 1.5 ml nitric acid, and 
diluted to 20 ml. The analysis was performed using a quantitative 
program. Protein concentration was determined spectrophotometri-
cally in 6 M GndHCl using calculated molar absorption coefficient 
56970 M- 1 [33]. 
2.5. Computer analysis 
The amino acid sequences were taken from sequence databases. The 
sequence databases TrEMBL, SWISSPROT and PIR were analyzed 
with the program Profilesearch from the GCG program package [34], 
The multiple sequence alignment was obtained with the GCG soft-
ware. 
3. Results and discussion 
The TH domain of Tec family members consists of a con-
served Btk motif and a proline-rich region [8]. The Btk motif 
has previously been found also in a GAPl protein of Droso-
phila melanogaster [35] and in a human interferon-y binding 
protein [36] adjacent to the PH domain (Table 1). Sequence 
analysis indicated that Ras GAP molecules from human (en-
try gl060909), bovine (R-RasGAP) [37], rat [38] and mouse 
(g972944) share the sequence similarity of PH domain and 
Btk motif. In addition, also human PtdIns(l,3,4,5)P4-binding 
protein belonging to the GAPl family [39] is related to Tec 
family N-terminus. The Ras GAP activity of this protein is 
specifically stimulated by PtdIns(l,3,4,5)P4 and inhibited by 
phosphohpids in vitro. Recently the mouse GAPl™ has been 
shown to bind PtdIns(l,3,4,5)P4 in a PH and TH domain 
dependent manner [40]. Murine GAPIII also contains a Btk 
motif, which is required for GTPase activity [41]. In all these 
Ras GAP molecules the PH domain and Btk motif are located 
in the C-terminus and the sequence similarity to the Tec fam-
ily is restricted to the PH domain and the Btk motif. No 
homologs were found from other organisms analysed. 
Although the complete genome of yeast has been sequenced 
[42] and found to contain numerous kinases [43] tyrosine ki-
nases are missing as well as TH domains. 
3.1. TH domain sequences 
The sequence alignment of TH domains (Fig. 1) indicates 
high conservation, even so that there are no gaps in any of the 
Btk motifs. Of the 25 residues in the Btk motif six are invar-
iant and one almost invariant as previously noted [8]. The first 
conserved residue is either Y or F in all the sequences. The 
following residues are HP except for in Bmx which carries HS. 
Then there are five variable intervening residues before an 
invariant G. Amino acids 14 and 15, CC, are invariant. The 
motif ends in the invariant GC pair (residues 24 and 25). In 
addition to these overall similarities, residue six is F in the Tec 
family and A in almost all of the GAP sequences. Also resi-
dues 1 (lysine), 9 (aspartate), 17 (glutamine) and 19 (lysine) 
are invariant in the Tec family. Thus, the Btk motif has both 
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Fig. 1. Alignment of proteins related to Btk family PH and TH domains. The TH domain contains two distinct motifs, the Btk motif and a 
proline-rich region (indicated with bars above the sequence). The numbering of the Btk motif is above the sequence as well as XLA causing 
mutations. The almost invariable residues are indicated by dark shading and as consensus sequence on the last line. The less conserved residues 
and group specific conservation is shown with light shading. The sequences are taken from databanks as follows: Btk, entry x58957 [1,2], Bmx 
(hsbmxgene) [6]; Itk (105631) [3,4]; Tec (ju0215) (Mano et al., unpublished); bovine R-Ras GAP (gl 17345) [37]; Drosophila melanogaster GAP1 
(gapl_drome) [35]; human GAP (gl060909) (M. Kobayashi et al., unpublished); human GAP1IP4BP (g963052) [39]; mouse GAPIII (g972944) 
[41]; rat GAPlm (g559375) [38]; interferon-y binding protein (a09787) [36]. 
general as well as family related similarities as also residues 12 
and 13 (WL) are almost invariant in GAP proteins. 
The TH module can be expressed and purified as a domain 
from E. coli (data not shown). The Btk motif contains a con-
served histidine and three cysteines, residues that are con-
served also in zinc finger proteins. Elemental analysis of the 
purified Btk PH-TH-SH3-SH2 construct indicated the protein 
to contain Zn2+ ion almost in equimolar ratio (1:0.94). The 
Btk PH domain with Btk motif has been shown to bind Zn2+ 
[44]. The metal can be released with dialysis giving a molar 
ratio of 1:0.12. Btk motif represents a new type of Zn2+ bind-
ing domain, since the organisation of the histidine and cys-
teine residues differs from those previously described [45]. 
The other half of the TH domain, PRR, is not present in 
the Ras GAP proteins (Fig. 1). This pattern contains tandem 
repeat in Btk and Tec. PRRs are commonly involved in pro-
tein-protein interactions with SH3 and WW domains [46,47]. 
The proline residues and hydrophobic amino acids are located 
at critical sites capable of forming polyproline type II (PPII) 
helix of RLP class [48]. The first half of the Btk PRR is 
identical with the single proline-rich stretch in Itk. The lysine 
residues in the beginning of both patterns govern the orienta-
tion of binding. Interestingly, the PRR of Itk has recently 
been shown to bind intramolecularly to its SH3 domain, 
thereby possibly regulating enzyme activity [49], as previously 
hypothesized for Btk [7]. 
3.2. The first TH domain missense mutations 
Although the gene defect has been determined for more 
than 400 XLA patients, the BTKbase mutation registry 
[27,28] does not contain missense mutations in the TH do-
main. Here we describe the first two TH domain mutations 
associated with XLA. These alterations affect the invariant 
CC pair in the middle of the Btk motif. C154S mutation 
(PIN C154S(1), accession number A0292) alters the invariant 
cysteine number 154 in the Btk motif (Fig. 2). The mutation is 
Fig. 2. Sequence analysis of genomic DNA of the BTK gene form patient BR, demonstrating a G to C transversion affecting nucleotide 593 
with the TH domain, resulting in mutation C154S. 
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Fig. 3. (A) Btk expression from XLA patients with mutations C154S and C155G. Btk expression was analysed also from a healthy individual 
as well as from a patient with a splice site mutation. (B) Lyn expression by probing the same filter as in A. (C) Immune complex kinase assay 
of phosphotyrosine containing Btk by immunoblotting with PY20H (from Signal Transduction Laboratories). Human Raji B-cell line was used 
as a positive control. 
due to G593 to C alteration changing TGC codon to TCC. 
The patient (BR) with moderately severe XLA was diagnosed 
at age of 8 years, but had had recurrent upper respiratory 
infections since the age of one year. The patient has no family 
history. Both B cells (1%) and immunoglobulins (IgG 1.66, 
IgM 0.18, and IgA 0.03 mg/ml) were markedly reduced. He 
failed to produce antibodies to diphtheria and tetanus and to 
polysaccharides. Following two immunizations with bacterio-
phage (|)X174 [50], he cleared the antigen normally, but made 
very little antibody (peak Kv during primary response was 
0.034, less than 1% of normal, and 2.18 following the second-
ary immunization, again less than 1% of normal). 
The second mutation identified alters T595 to G changing 
TGC to GGC resulting in C155 to G mutation (PIN 
C155G(1), accession number A0357). The mutation destroys 
a Tsel restriction site. This patient has clinically a mild disease 
although no B cells could be detected. The diagnosis was 
made at the age of 35 years. In this family there are six 
affected males in two generations. 
Total cell lysates of mononuclear cells isolated from the 
XLA patients with mutations C154S and C155G, respectively, 
were analysed for Btk and Lyn expression and Btk kinase 
activity (Fig. 3). Btk expression was absent in both patients 
as well as in a patient with a splice site mutation. Normal 
quantity of Btk was found in the cells of a healthy control 
suggesting that the mutations affect the structure of the pro-
tein. As an internal control, the presence of Lyn was con-
firmed (Fig. 3B) in all cell lysates. No traces of Btk were 
found even after immunoprecipitation of total cell lysates of 
patients with mutations C154S and C155G (Fig. 3C). 
The two mutations identified in the Btk TH domain appear 
in the conserved Zn2+ binding cysteines thus destroying the 
binding site and affecting both folding and stability. The 3D 
structure indicates that the cysteines are crucial for metal 
binding [44] and a substitution in any of them would affect 
folding. This is evident also from expression studies, since the 
mutated proteins that are efficiently expressed in E. coli could 
not be purified although the proteins were mainly soluble after 
lysis (Fig. 4). Similarly, some PH domain mutations affect the 
structure of the expressed proteins [44]. 
A previously reported missense mutation located in the TH 
domain [51] affected the first proline-rich repeat in the PRR 
and could cause XLA due to preventing SH3 domain binding. 
However, this patient has also another mutation (PIN 
#G54X56/E205D(1)) and it is not possible to define which 
of these alterations occurred first. The substitution could be 
a previous pathological change in the family, which might 
have gained later another frameshift mutation in the gene 
encoding already non-functional protein. The mutations in 
the Zn2+ binding residues affect the structure and stability 
of Btk. It is highly likely that substitutions in the PRR will 
also cause XLA, although no examples are known to date. 
Acknowledgements: Dr. Paul Ek is thanked for performing element 
analyses. This work was supported by Biocentrum Helsinki, Finnish 
Academy, Karolinska Institute Foundation, the Swedish Cancer Soci-
ety, the Swedish Medical Research Council, Ake Wiberg Foundation, 
Magn. Bergvall Foundation, National Institute of Health (HD17427) 
and the March and Dimes Birth Defects Foundation (6-0330). A 
portion of this work was conducted through Clinical Research Center 
of the University of Washington (RR-37). 
M. Vihinen et al.lFEBS Letters 413 (1997) 205-210 209 
Fig. 4. (A) The expression level of the native and mutation-contain-
ing PH-TH proteins in E. coli analysed with SDS-PAGE. Lanes: 
la, non-induced whole cell preparate; 2, induced whole cell prepa-
rate of native PH-TH; 3, supernatant of lysate of native PH-TH; 
4, supernatant of lysate of C154S; 5, supernatant of lysate of 
C155G. Molecular weight markers (M) contained aprotinin. (B) 
Identification of human Btk PH-TH constructs by Western blotting. 
Lanes: lb, whole cell preparate of E. coli BL21 (DE3) containing 
pBAT4; 2-5 as above. The immunoblot was developed using ECL. 
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